News
Silo Pharma
SILO · NASDAQ
$1.20−$0.03 (−2.44%)TodayMarket closed ·
Prev close $1.23
Latest news
- Press releaseGlobe Newswire
Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
- Press releaseGlobe Newswire
Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
- Press releaseGlobe Newswire
Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseGlobe Newswire
Silo Pharma Granted European Patent Covering Novel PTSD Therapy
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- Press releaseGlobe Newswire
Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform
- Press releaseGlobe Newswire
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
- NewsVandana Singh
Silo Pharma Unit Eyes Faster AI Agent Development Through AMD Partnership
- Press releaseGlobe Newswire
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
- NewsLekha Gupta
Consumer Tech News (July 6-10): Micron Plans $250B US Expansion, Apple Signs $30B Broadcom Deal & More
- Press releaseGlobe Newswire
Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
- NewsVandana Singh
Certara, Silo Pharma Advance AI Agent Strategies with Nvidia Initiatives
- Press releaseGlobe Newswire
Silo Pharma Subsidiary QwikAgents Set to Advance Enterprise AI Agent Platform through NVIDIA Developer Program
- Press releaseGlobe Newswire
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
- Press releaseGlobe Newswire
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
- Press releaseGlobe Newswire
Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Press releaseGlobe Newswire
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
- Press releaseGlobe Newswire
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseGlobe Newswire
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
Silo Pharma Highlights Pipeline Strength Amid Rising U.S. Policy Focus On Psychedelic Mental Health Treatments.
- Press releaseGlobe Newswire
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsRishabh Mishra
Stock Market Today: Dow, S&P 500 Futures Drop Ahead Of Trump's 'Power Plant Day' Deadline— UnitedHealth, Silo Pharma, Phillips 66 In Focus (UPDATED)
- NewsAvi Kapoor
Why Silo Pharma Shares Are Trading Higher By Around 52%; Here Are 20 Stocks Moving Premarket
- Press releaseGlobe Newswire
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- Press releaseGlobe Newswire
Silo Pharma Announces Share Buyback Program
- Press releaseGlobe Newswire
Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio
- Press releaseGlobe Newswire
Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.